Sunday 18 October 2026
Export ARMP’s income statement to Excel — free account
Armata Pharmaceuticals, Inc.
ARMP Healthcare Biotechnology
Armata Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.9 million, down 5.22% from fiscal 2024. In the quarter to June 2026, revenue grew 15.7%, EPS grew 548.9%, free cash flow fell 18.0% and total debt rose 152.4%, each against the same quarter a year earlier.
3.37
0.28
+9.06%
Follow ARMP
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
2 | 4 | — | — | — | — | 2 | 2 | 3 | 3 |
P/E ratio |
0.00 | 0.00 | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
(33.16) | (52.82) | — | — | (6.60) | (3.17) | (4.26) | (5.15) | (7.08) | (10.15) |
P/S ratio |
18.55 | 56.07 | — | — | 58.03 | 29.52 | 6.85 | 24.69 | 9.98 | 46.41 |
Altman Z″-Score (non-manufacturers) |
(74.93) | (120.73) | — | — | (16.85) | (10.21) | (9.96) | (13.11) | (18.84) | (25.10) |
P/FCF ratio |
0.00 | 0.00 | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Beneish M-Score |
— | — | — | — | — | 1.57 | (1.18) | (4.33) | (2.15) | (12.48) |
P/Operating CF |
(3.22) | (2.72) | — | — | (7.76) | (15.36) | (3.60) | (13.80) | (8.44) | (34.10) |
P/B ratio |
0.50 | 0.83 | — | — | 2.59 | 5.20 | 1.05 | 0.00 | 0.00 | 0.00 |
Price to Tangible BV |
0.51 | 0.86 | — | — | 3.18 | 6.03 | 1.16 | 0.00 | 0.00 | 0.00 |
EV/Sales |
(3.42) | 11.44 | — | — | 62.18 | 35.72 | 13.02 | 42.85 | 22.68 | 123.75 |
EV/EBITDA |
0.04 | 0.00 | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
0.08 | (0.14) | — | — | (2.87) | (6.78) | (2.21) | (4.09) | (4.05) | (23.56) |
EV/FCF |
0.08 | (0.14) | — | — | (2.75) | (6.42) | (2.07) | (3.49) | (3.85) | (23.07) |
Quick Ratio |
1.61 | 2.61 | 4.76 | 1.24 | 1.52 | 2.76 | 0.94 | 1.03 | 0.21 | 1.02 |
Current Ratio |
1.78 | 2.74 | 5.10 | 1.36 | 1.62 | 3.11 | 1.09 | 1.16 | 0.23 | 1.19 |
Net Debt/EBITDA |
0.21 | 0.33 | 0.59 | 0.17 | (0.17) | (1.22) | (0.94) | (1.72) | (2.07) | (7.07) |
Debt/Assets |
4.42% | 0.00% | 0.00% | 11.25% | 33.28% | 54.45% | 50.94% | 83.68% | 109.20% | 334.18% |
Debt/Equity |
0.08 | 0.00 | 0.00 | 0.20 | 0.70 | 1.50 | 1.35 | (2.57) | (1.97) | (1.18) |
Asset Turnover |
0.01 | 0.01 | 0.00 | 0.00 | 0.03 | 0.08 | 0.07 | 0.05 | 0.06 | 0.06 |
Operating CF/Net income |
0.44 | 0.72 | 0.64 | 0.80 | 0.82 | 1.02 | 0.88 | 0.69 | 1.99 | 0.15 |
Capex/Depreciation |
(0.76) | (0.16) | (0.60) | (0.10) | (0.74) | (1.12) | (2.48) | (8.37) | (1.42) | (0.35) |
Interest Coverage |
— | — | (17.43) | (21.22) | (34.37) | (372.22) | (1,274.00) | (15.57) | (3.95) | (2.21) |
| (216.39%) | (147.11%) | (216.56%) | (174.80%) | (132.62%) | (104.65%) | (120.10%) | (3,439.35%) | 47.24% | 130.37% | |
| (97.80%) | (87.66%) | (130.06%) | (97.40%) | (68.28%) | (42.38%) | (44.59%) | (71.11%) | (20.47%) | (212.83%) | |
ROIC |
(303.45%) | (388.51%) | 0.00% | (108.07%) | (60.34%) | (28.04%) | (32.97%) | (69.60%) | (71.53%) | (77.26%) |
Return on Tangible Assets |
(631.04%) | (303.28%) | (144.27%) | (491.52%) | (358.45%) | (186.72%) | (637.49%) | (452.78%) | 79.81% | (1,249.00%) |
Average Days of Receivables |
0.00 | 0.00 | — | — | 248.80 | 243.85 | 565.33 | 271.03 | 52.49 | 35.13 |
Research and Development Expense of Revenue |
2,183.85% | 2,505.22% | 0.00% | 0.00% | 1,755.04% | 447.36% | 635.75% | 745.64% | 665.37% | 483.63% |
Selling, General and Administrative Expense of Revenue |
3,235.77% | 6,600.00% | 0.00% | 0.00% | 967.92% | 185.09% | 135.02% | 257.21% | 254.81% | 253.04% |
Intangible Assets out of Total Assets |
0.02 | 0.02 | 0.02 | 0.14 | 0.09 | 0.05 | 0.04 | 0.04 | 0.04 | 0.05 |
Share Based Compensation of Revenue |
767.31% | 1,060.00% | 0.00% | 0.00% | 422.24% | 64.42% | 56.37% | 20.71% | 55.91% | 53.22% |
Graham Net Nets |
(0.44) | 0.31 | — | — | (0.20) | (0.22) | (0.87) | (0.99) | (1.84) | (1.25) |
Graham Number |
0.00 | 0.00 | — | — | 0.00 | 0.00 | 0.00 | 6.18 | 3.94 | 25.52 |
Earnings Yield |
(531.03%) | (345.69%) | — | — | (47.65%) | (17.70%) | (99.09%) | (61.61%) | (28.11%) | (76.43%) |
Free Cash Flow Yield |
(225.71%) | (143.46%) | — | — | (39.03%) | (18.83%) | (91.96%) | (49.68%) | (58.94%) | (11.56%) |
Revenue per Share |
3.70 | 0.25 | 0.00 | 0.00 | 0.05 | 0.19 | 0.16 | 0.13 | 0.14 | 0.14 |
Operating CF per Share |
(150.87) | (20.16) | (2.28) | (1.99) | (1.11) | (0.98) | (0.95) | (1.31) | (1.04) | (0.71) |
Capex per Share |
(3.97) | (0.13) | (0.17) | (0.02) | (0.05) | (0.05) | (0.06) | (0.23) | (0.05) | (0.01) |
Free Cash Flow per Share |
(154.84) | (20.29) | (2.46) | (2.01) | (1.16) | (1.03) | (1.01) | (1.54) | (1.09) | (0.73) |
Cash per Share |
81.24 | 11.25 | 2.08 | 0.77 | 0.59 | 0.43 | 0.43 | 0.37 | 0.26 | 0.24 |
Shareholders Equity per Share |
138.31 | 16.95 | 1.65 | 1.86 | 1.15 | 1.05 | 1.05 | (0.89) | (1.33) | (6.03) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
138.31 | 16.95 | 1.65 | 1.86 | 1.15 | 1.05 | 1.05 | (0.89) | (1.33) | (6.03) |
Free Cash Flow |
(10.88) | (9.25) | (11.44) | (15.71) | (19.09) | (24.88) | (34.69) | (55.56) | (39.43) | (26.30) |
Working Capital |
2.78 | 3.42 | 8.33 | 1.78 | 4.14 | 10.18 | 2.17 | 2.69 | (36.94) | 1.72 |
Capital Expenditures |
(0.28) | (0.06) | (0.81) | (0.13) | (0.82) | (1.30) | (2.21) | (8.13) | (1.88) | (0.54) |
Net Current Asset Value |
(2.12) | 1.98 | 3.51 | (4.20) | (9.81) | (29.38) | (32.71) | (111.28) | (123.15) | (284.81) |
EV/EBIT |
0.04 | 0.00 | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
1.07 | 0.50 | 0.00 | 0.00 | 1.00 | 0.29 | 0.40 | 1.80 | 0.36 | 0.11 |
Price to Operating Income |
0.00 | 0.00 | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.34 | 0.46 | 0.42 | 0.62 | 0.54 | 0.53 | 0.25 | 0.08 | 0.10 | 0.13 |
Cash ROIC |
(67.04%) | (71.91%) | (65.89%) | (66.90%) | (45.84%) | (33.77%) | (34.78%) | (87.13%) | (70.84%) | (55.95%) |
Accounts Receivable Turnover |
0.00 | 0.00 | — | — | 2.40 | 2.52 | 0.96 | 0.76 | 2.52 | 8.07 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | — | — | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | — | — | 0.00 | — | — | — |
Average Receivables |
— | — | — | — | 0.34 | 1.78 | 5.76 | 5.95 | 2.05 | 0.61 |
Average Payables |
1.89 | 2.35 | 1.25 | 0.91 | 1.60 | 2.10 | 4.15 | 5.86 | 3.87 | 1.88 |
Average Assets |
24.82 | 14.65 | 12.84 | 20.00 | 32.48 | 54.64 | 82.80 | 97.10 | 92.40 | 81.66 |
Average Common Equity |
11.22 | 8.73 | 7.71 | 11.14 | 16.73 | 22.13 | 30.74 | 2.01 | (40.04) | (133.31) |
Columns are period end dates